In 1996 Mad Cow Disease (BSE) had been linked to a disease in humans, causing a sizable panic and collapse in the beef markets in the United Kingdom and Ireland. Enter IdentiGEN, founded the same year in Dublin. The company uses the science of DNA fingerprinting to track the origins of food products. The beef market collapse highlighted the importance of consumer confidence in the controls and origin of meat. And IdentiGEN’s development of the first application of DNA fingerprinting of cattle reduces the risk and impact of food safety crises, similar to the BSE scare. “Just like people, each…
Read the full article


Lawrence was the first research and development laboratory location in the U.S. for Argenta, an animal health company founded in New Zealand that invents, develops, and manufactures pharmaceuticals for both pets and farm animals. The Bioscience & Technology Business Center offered all that Argenta needed to put its R&D paws down in the North American market — available lab space, a central location close to a number of the company’s key clients, access to a world-class pharmacy school, and a home right in the middle of the KC Animal Health Corridor, the largest concentration of animal health companies in the…
Read the full article

KanPro Research

KU spinout creates challenging proteins for university, corporate clients

LAWRENCE — A University of Kansas scientist has launched a startup company designed to tackle the most complicated protein production for academic and industrial clients. KU biochemist Philip Gao has founded KanPro Research Inc., a contract research company that produces challenging proteins for university and corporate researchers in the life sciences, biotechnology and medicine. In addition to protein production, KanPro provides consulting services for clients with protein needs. “Proteins are widely used by academic researchers and bioscience companies,” said Gao, director of KU’s Protein Production Group and president of the company. “But for clients with highly specialized and complicated protein…
Read the full article


Developing innovative new ways to treat diseases in people and animals

HylaPharm is a university spinout company developing cancer chemotherapies targeted for potentially deadly, locally advanced cancers that affect nearly 200,000 Americans each year. Unlike conventional chemotherapy that enters vein and diffuses all over the body before getting to the tumor, our patented drug HylaPlat™ is injected into tumor or surrounding at-risk tissues. This results in very high tumor dosing. HylaPlat™ then drains into local lymph nodes, which is where tumors generally metastasize first. Our technology makes treatment of certain types of cancer, including breast cancer and head and neck cancer, both safer and more effective in animal trials. HylaPlat™ has already…
Read the full article